Drug Target Validation, Prioritization and Discovery
Product Overview
There are no drugs effective for Heart Failure with preserved ejection fraction (HFpEF) and despite therapies for Heart Failure with reduced EF (HFrEF), mortality rates remain high. To validate, prioritize and discovery new targets, we are building a large clinical omics dataset of several thousand participants, which includes Whole Genome Sequencing (WGS) and detailed and longitudinal clinical and imaging data, of both major Heart Failure subtypes from Heart Failure units. We also include an Incident HF study data.